Sallie Mae Chief Financial Officer to Present at Credit Suisse Financial Services Forum

Sallie Mae® (Nasdaq: SLM) announces that Chief Financial Officer Steve McGarry will address attendees at the Credit Suisse Financial Services Forum on February 14 at 8:35 a.m. ET.

(Neutral)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

01/31/2023 - 04:31 PM

NEWARK, Del.--(BUSINESS WIRE)-- Sallie Mae® (Nasdaq: SLM) today announced Chief Financial Officer Steve McGarry will speak at the Credit Suisse Financial Services Forum on Tuesday, Feb. 14, at 8:35 a.m. ET.

A live audio webcast and replay will be available at SallieMae.com/investors.

Sallie Mae (Nasdaq: SLM) believes education and life-long learning, in all forms, help people achieve great things. As the leader in private student lending, we provide financing and know-how to support access to college and offer products and resources to help customers make new goals and experiences, beyond college, happen. Learn more at SallieMae.com. Commonly known as Sallie Mae, SLM Corporation and its subsidiaries are not sponsored by or agencies of the United States of America.

Category: Corporate and Financial

View source version on businesswire.com: https://www.businesswire.com/news/home/20230131006047/en/

Media
Rick Castellano
302.451.2541
rick.castellano@salliemae.com

Investors
Melissa Bronaugh
571.526.2455
Melissa.Bronaugh@SallieMae.com

Source: Sallie Mae

Keep reading

More on SLM

All SLM news

Trending in the feed

ARGX

argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease Open the live feed